819 Capital Partners has acquired a stake in CiMaas, a biotech company specializing in Natural Killer cell therapy aimed at improving cancer treatment and patient outcomes.
Target Information
Founded in 2015, CiMaas BV is a spin-off from Maastricht University and Maastricht University Medical Center+ (UM/Maastricht UMC+). This biotech company is committed to revolutionizing cancer treatment through the development of Natural Killer (NK) cell therapies aimed at addressing unmet needs in metastatic and late-stage cancers. Effective cancer treatments currently cure only 60% of patients in Western countries and often fall short in advanced cases, highlighting the critical need for innovative solutions.
CiMaas focuses on providing safe and effective therapeutic options that not only minimize side effects but also enhance patients' quality of life. By leveraging various components of the immune system, the company strives to deliver robust and sustainable treatments that instill hope in patients facing severe health challenges.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview
The biotechnology sector in the Netherlands, particularly in the realm of cancer therapeutics, has witnessed substantial growth in recent years. With a strong foundation in research and development stemming from academic institutions, the
Similar Deals
Frazier Life Sciences, Droia Ventures → Alesta Therapeutics
2025
Brightlands Venture Partners → Novenda Technologies
2023
819 Capital Partners
invested in
CiMaas
in 2024
in a Series A deal